Saltar al contenido
MilliporeSigma
Get up to 22% off for Pi Day until 3/26.Save Now

Hyperammonemia in a patient with late-onset ornithine carbamoyltransferase deficiency.

Journal of Korean medical science (2012-05-09)
Dae Eun Choi, Kang Wook Lee, Young Tai Shin, Ki Ryang Na
RESUMEN

Ornithine carbamoyltransferase (OTC) deficiency is a urea cycle disorder that causes the accumulation of ammonia, which can lead to encephalopathy. Adults presenting with hyperammonemia who are subsequently diagnosed with urea cycle disorders are rare. Herein, we report a case of a late-onset OTC deficient patient who was successfully treated with arginine, benzoate and hemodialysis. A 59-yr-old man was admitted to our hospital with progressive lethargy and confusion. Although hyperammonemia was suspected as the cause of the patient's mental changes, there was no evidence of chronic liver disease. A plasma amino acid and urine organic acid analysis revealed OTC deficiency. Despite the administration of a lactulose enema, the patient's serum ammonia level increased and he remained confused, leading us to initiate acute hemodialysis. After treatment with arginine, sodium benzoate and hemodialysis, the patient's serum ammonia level stabilized and his mental status returned to normal.

MATERIALES
Número de producto
Marca
Descripción del producto

Supelco
Benzoato de sodio, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Benzoato de sodio, ReagentPlus®, 99%
Sigma-Aldrich
Benzoato de sodio, puriss., meets analytical specification of Ph. Eur., BP, FCC, E211, 99.0-100.5% (calc. to the dried substance), powder
Sigma-Aldrich
Benzoato de sodio, BioXtra, ≥99.5%
Sigma-Aldrich
Benzoato de sodio, purum p.a., ≥99.0% (NT)
Sigma-Aldrich
Benzoato de sodio, SAJ special grade, ≥99.0%